Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Pre-Treatment Period	STARTED	Nivolumab 240 mg	371
Pre-Treatment Period	STARTED	Sorafenib 400 mg	372
Pre-Treatment Period	COMPLETED	Nivolumab 240 mg	367
Pre-Treatment Period	COMPLETED	Sorafenib 400 mg	363
Pre-Treatment Period	NOT COMPLETED	Nivolumab 240 mg	4
Pre-Treatment Period	NOT COMPLETED	Sorafenib 400 mg	9
Treatment Period	STARTED	Nivolumab 240 mg	367
Treatment Period	STARTED	Sorafenib 400 mg	363
Treatment Period	COMPLETED	Nivolumab 240 mg	0
Treatment Period	COMPLETED	Sorafenib 400 mg	0
Treatment Period	NOT COMPLETED	Nivolumab 240 mg	367
Treatment Period	NOT COMPLETED	Sorafenib 400 mg	363

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02576509/flow